Ultimele actualizari :
19/11/2024
Citostatic   Blinatumomab  
Injectabil
Stabilitatea in solutie Stabilitatea in amestec Factorii care influenteaza stabilitatea Compatibilitate Microunde Bibliografie pdf

Denumirea comerciala   Denumirea comerciala     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Blincyto Argentina, Australia, Austria, Belgia, Brazilia, Chilli, Danemarca, Elvetia, Franta, Germania, Irlanda, Italia, Japonia, Luxemburg, Marea Britanie, Mexic, Norvegia, Peru, Romania, Slovenia, Spania, SUA, Suedia, Ungaria
Bibliografie   Injectabil   Bibliografie : Blinatumomab  
tip publicare
2296 Laborator Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3774 Laborator Blinatumomab - (Blincyto®) - Summary of Product Characteristics
Amgen 2016
3976 ziar Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218

  Mentions Légales